Abstract: Parnaparin is a low-molecular-weight heparin that has widely shown its efficacy and safety in prevention of venous thromboembolism, in the treatment of chronic venous disorders, and in the treatment of venous and arterial (stable and unstable angina, acute ST-segment elevation myocardial infarction) thrombosis. Parnaparin at the respective dosages of 3200, 4250, 6400, or 12800 IUaXa for a period ranging from 3 to 5 days to 6 months, is usually administered subcutaneously by means of once-daily regimen and is better tolerated than unfractionated heparin at the injection site. In the variety of commercially available low-molecular-weight heparins, parnaparin represents a useful therapeutic option, even though little evidence is available comparing the superiority or the equivalent efficacy and safety of parnaparin to that of the unfractionated heparin or placebo. This review summarizes the available literature on the use of parnaparin in different settings of cardiovascular diseases, including papers published during the past year and ongoing studies.
Introduction
Anticoagulant therapy, such as heparin, has been used for at least 40 years in the management of chronic venous disorders and plays an important role in the prevention and treatment of venous and arterial thrombosis. 1 Low-molecular-weight heparins (LMWHs) have been extensively investigated in a large number of randomized clinical trials. Where shown to be safe and effective they have been used as drugs for the prevention and treatment of venous thromboembolism (VTE), and for the treatment of acute coronary syndromes (ACS) and peripheral arterial occlusive disease (PAOD), and for the management of chronic venous disorders (CVD), including chronic venous insufficiency (secondary to post-thrombotic syndrome or varicose disease), and varicophlebitis or thrombophlebitis of nonvaricose veins.
Among other LMWHs, parnaparin (parnaparin sodium; Fluxum ™ ) 1 has been successfully employed for the prevention and the treatment of VTE and CVD, while its use in the management of ACS and PAOD has been less extensively investigated. [2] [3] [4] The present review focuses on the pharmacological properties and clinical uses of parnaparin, especially in the management of venous thromboembolism, chronic venous disease, PAOD, and coronary artery disease.
Note on dosage
Dosages of parnaparin reported in this review (3200, 4250, 6400 and 12800 IUaXa) were calculated according to the European Pharmacopea Standard of LMWHs, and are equivalent to those reported in clinical papers published between the early 1980s and the mid 1990s (7500, 10000, 15000 and 30000 aXaU, respectively), which in turn were based on the 4th International Standard of Unfractionated Heparin (UFH).
Pharmacology of parnaparin Pharmacodynamics
Parnaparin is a LMWH with a mean molecular weight of approximately 4.5 kDa, obtained with a specif ic fragmentation procedure that warrants the homogeneity of each fragment in terms of molecular weight and length, in order to optimize and maintain an anti-Xa/anti-IIa ratio of 4. 3, 5 The pharmacodynamics of subcutaneous parnaparin were investigated in studies in vitro, in healthy volunteers; and in patients with peripheral vascular diseases, acute coronary syndromes and undergoing surgery.
By in vitro studies, parnaparin was shown to possess the following properties: -inhibition of the thrombin activatable fibrinolytic inhibitor (TAFI) less potently than UFH (with inhibition of 50% of relative concentrations [IC50] of 0.6 to 0.8 vs 0.01 U/mL, respectively), similarly to dalteparin and tinzaparin, and more potently than enoxaparin (IC50  1.0 U/mL); 6 active control of the anticoagulant effect in the presence of activated platelets, greater than UFH and independent of the concomitant intake of aspirin; 7 inhibition of aggregate formation of platelets/ polymorphonuclear leukocytes and of the expression of tissue factor and L-selectin in leukocytes; prevention of leukocyte degranulation and of fibrinogen binding to platelets more potently than UFH and enoxaparin. 8, 9 Studies in healthy volunteers showed that parnaparin inhibits factor Xa (antithrombotic effect) more efficiently than factor IIa (anticoagulant effect), resulting in a greater anti-Xa/ anti-IIa activity ratio than UFH. [10] [11] [12] The inhibition of factor Xa occurs intensively and rapidly (anti-Xa activity about 0.2, 0.5 and 0.9 aXaU/mL, approximatively 2 to 4 hours after administration of parnaparin 3200, 6400 and 12800 IUaXa, respectively), is dose-dependent, and persists for many hours after administration of a single bolus of subcutaneous parnaparin (ranging from 6 to 12 hours after administration of parnaparin 3200 or 6400 IUaXa, with demonstrable anti-Xa activity still occurring at 20 hours with the parnaparin 6400 IUaXa dose; in contrast, the anti-IIa activity was undetectable at 4, 8 and 12 hours postadministration).
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Clinical studies conducted in patients undergoing bariatric surgery reported that the obesity (BMI  45 kg/m 2 ) does not influence parnaparin anti-Xa activity. 13 When fixed-dose parnaparin is employed as thromboprophylaxis in obese patients, a strong negative correlation between total body weight and anti-factor Xa levels is observed. These findings suggest that weight-based prophylactic dosing might be preferable to fixed-dosing for obese patients, and especially those with severe obesity (BMI 52.4 kg/m 2 ).
14 A similar anti-factor Xa activity inhibitory effect, greater than UFH, is reported both in patients undergoing surgery [15] [16] [17] and in patients with a peripheral arterial occlusive disease (PAOD). 18 Moreover, in PAOD and surgical patients, as in patients with acute myocardial infarction (MI), parnaparin has been shown to have a weak effect on activated partial thromboplastin time (aPTT) (only the highest dose of 12,800 IU aXa caused a peak value reaching the lower limit of clinical significance), 10, 11 to decrease fibrin formation in a proportional dose-dependent manner, [18] [19] [20] and to reduce whole blood viscosity. 20, 21 Finally, in patients with unstable angina (UA) or acute ST-segment elevation myocardial infarction (STEMI), parnaparin was able to reduce platelet count to a lesser extent than UFH.
22,23

Pharmacokinetics
As with other LMWHs, the assessment of the main pharmacokinetic properties after administration of a single dose of parnaparin have been made indirectly ex vivo by measuring anti-Xa activity, considered to be the main antithrombotic mechanism.
In healthy volunteers the peak inhibition of factor Xa (E max ) after subcutaneous administration of parnaparin is dose-dependent (0.27 IU/mL after administration of 3200 IUaXa, 0.58 IU/mL with 6400 IUaXa). [10] [11] [12] After intravenous administration E max is approximately 5-fold greater than after subcutaneous administration of the same dose (eg, mean E max 1.35 IU/mL after iv administration of 3200 IUaXa). 10, 12 Parnaparin peak anti-Xa activity (t max ) occurs rapidly after administration, approximately 3 hours and 5 minutes when the subcutaneous or intravenous route are used, respectively, regardless of dose. 10, 12 Independently of the injection site (abdomen, gluteal region, deltoid), the bioavailability of the drug was 90%. 24, 25 No signs of drug accumulation after repeated once-daily subcutaneous administration for 7 days were detected. 26 Parnaparin is metabolized in the liver and kidneys and, as with other LMWHs, is cleared principally by the renal route; 3 however, the effects of renal or hepatic impairment on its pharmacokinetics have not been reported. In general, Clinical use of parnaparin Dovepress submit your manuscript | www.dovepress.com Dovepress the clearance of the anti-Xa effect of LMWHs is strongly related to the creatinine clearance (CrCl), the cutoff value to avoid accumulation being a ClCr  30 mL/min, and renal insufficiency is associated with an increased risk of bleeding complications when therapeutic doses of LMWHs are used. Conversely, the administration of prophylactic doses is not reported to confer an higher bleeding risk. 27 Therefore, it is likely that prophylactic doses of parnaparin may be safely administered in patients with severe renal insufficiency; however, if therapeutic doses are needed, weight-adjusted low-doses of parnaparin or UFH (which is not cleared through the kidneys) should be used.
3,27
Search strategy
We started with a Medline search, using the keyword "parnaparin" [All Fields], with the limit "human", which yielded 23 papers published between 1993 and 2007, of which 5 were reviews. We also crosschecked the references of all relevant articles and reviews in order to retrieve more evidence. Finally, we asked Alfa Wasserman (Bologna, Italy) to provide us with all the documentation inherent to the clinical development of parnaparin.
Overview of therapeutic efficacy
Clinical experience with subcutaneous parnaparin in various clinical situations is summarized in Tables 1 to 5 .
Prevention of venous thromboembolic disease (Table 1) Subcutaneous parnaparin, administered once or twice daily at 3200 or 6400 IuaXa, was compared with placebo 28, 29 or subcutaneous UFH [14] [15] [16] [30] [31] [32] [33] [34] [35] [36] [37] [38] 22 days. Prophylactic therapy was generally initiated 2 hours before low-to medium-risk thromboembolic surgery, and 12 hours before high-risk surgery. In a cohort study of patients undergoing minor orthopedic procedures, parnaparin was initiated 3 to 9 hours postoperatively. 45 The eff icacy endpoints were: frequency of DVT, i nve s t i ga t e d w i t h ve n og r a p hy, u l t r a s o n og r a p hy (continuous-wave Doppler, compression ultrasound, color-coded Doppler ultrasound), fibrinogen uptake test or plethysmography (impedance, strain-gauge); and the frequency of pulmonary embolism (PE), which was assessed with ventilation/perfusion lung scan or chest X-ray, if suspected on clinical grounds (Table 1) .
In general, although the methodological quality of the trials published before 1990 was modest, subcutaneous parnaparin demonstrated to be effective in the prevention of DVT and PE (Table 1) . Specifically, subcutaneous parnaparin was at least as effective as UFH in preventing DVT across all clinical trials; and in two large studies in patients undergoing general surgery (n = 610, and n = 173, respectively), 32, 35 the incidence of DVT in the parnaparin (3200 or 6400 IUaXa once-daily) group was statistically significantly lower than in the UFH (5000 IU 2-or 3-times daily) group (3.2% vs 6.3%, P  0.05; and 1.1% vs 7.1%, P = 0.038, respectively).
The low number of events recorded did not allow meaningful statistical comparisons for the frequency of PE. (Table 2) Subcutaneous parnaparin, administered once or twice daily at 6400 or 12,800 IuaXa, was compared with intravenous 46 or subcutaneous 47, 48 UFH, or with nadroparin 49 in 4 randomized trials of adult patients with objectively proven DVT. In all studies parnaparin was at least as effective as the comparator in preventing recurrent extending DVT and PE, with a similar safety profile. The short duration of patient observation (at most 6 months), combined with the choice of noninvasive tests to assess the endpoints (frequency of recurrent/extending DVT, and frequency of PE) is very likely responsible for the low frequency of events observed.
Treatment of deep-vein thrombosis
Chronic venous disease (Table 3) The efficacy of parnaparin in the treatment of postphlebitic syndrome or chronic venous insufficiency of the lower limbs was compared with that of UFH in 5 randomized trials. [51] [52] [53] [54] [55] Treatment duration ranged from 30 to 90 days. These small-sample (number of patients included = 46 to 92) Dovepress trials failed to show any statistically significant difference in terms of efficacy between parnaparin and UFH; although both parnaparin and UFH were generally effective in improving clinical and instrumental outcomes evaluated at baseline and at the end of treatment. 51, [53] [54] [55] In one double-blind study, 52 parnaparin (6400 IUaXa) proved to be statistically significantly better than UFH and than a lower parnaparin dose (3200 IUaXa) in reducing the intensity of symptoms (evaluated on a clinical scale), the ankle diameter, and in increasing venous outflow (as assessed by strain-gauge plethysmography).
Peripheral arterial occlusive disease (Table 4) Subcutaneous parnaparin (6400 IUaXa once-daily) was compared with placebo in 6 small (number of patients = 33 to 36) randomized trials [56] [57] [58] [59] [60] [61] or with UFH in one nonrandomized study, 13 performed over 6 56-61 or 7 13 months. All randomized studies, except one 58 were double-blinded, and conducted in patients with stage II disease (Leriche-Fontaine classification). Endpoints included the evaluation of pain-free walking distance (by treadmill) or time of rest and peak calf blood flow (by strain-gauge plethysmography), and of the ankle-brachial index (ratio between ankle and brachial artery pressures, normal ratio being 0.9).
In 4 of these studies 56,58-60 parnaparin significantly improved pain-free walking distance or time, ankle-brachial index, or both, as compared to placebo. In the remaining 3 studies, 13, 57, 61 in which only within-group analysis was available, baseline values for pain-free walking distance, blood flow, or ankle-brachial index were significantly increased at the end of the treatment period in the parnaparin group 57 or in both parnaparin and the UFH 13 or placebo 61 groups, respectively.
Acute coronary syndromes (Table 5) Parnaparin was compared with placebo in a small (n = 29), randomized, double-blind study of patients with stable angina, 62 and with UFH in 2 large-sample randomized nonblinded trials of patients with unstable angina 21 and STEMI. 23 The two larger trials 21, 23 used composite efficacy hard endpoints, including death, while the smaller used only substitute endpoints. 62 In the two larger trials, parnaparin yielded a statistically significant reduction in the frequency of the primary efficacy endpoint versus UFH, 21, 23 while in the smaller trial a statistically significant improvement in the primary efficacy endpoint was observed only in the 
Clinical update
Based on our search strategy, we were able to retrieve 1 full paper, 63 and 2 congress abstracts 64, 65 dealing with clinical uses of parnaparin which were published during 2008. The first, a small-sample (n = 10) open-label study, 63 evaluated the efficacy of 3 different oral dosages (70, 140 and 210 mg once daily) of parnaparin in the treatment of mild-to-moderate relapse of left-sided ulcerative colitis, over 8 weeks. The endpoints were standardized clinical and endoscopic activity of the disease. At the end of the treatment, 7 patients (70%) were in clinical remission, only 1 achieving endoscopic healing, and standardized clinical scores were statistically significantly improved from baseline. The second, a randomized open multicenter dose-finding study of patients (n = 66) with severe obesity (BMI  36) undergoing bariatric surgery, evaluated the effect of 2 parnaparin doses (4250 IUaXa or 6400 IUaXa, administered once daily for 9 ± 2 days) on anti-Xa levels, evaluated the day before operation, and at 4 and at 6 days after operation. The authors observed that with the administration of 4250 IUaXa the anti-Xa levels were within the expected activity range in 98.3% of the cases, while with 6400 IUaXa the anti-Xa activity was above the specified prophylactic range in 62.3 of the cases. 64 The third study reported the results of a multicenter, randomized, double-blind, controlled trial comparing the efficacy and safety of aspirin (100 mg/daily for 3 months) versus parnaparin (12,800 IUaXa for 7 days followed by 6400 IUaXa for a total of 3 months) for treatment of retinal vein occlusion (RVO). The primary efficacy endpoint of the study was the incidence of functional worsening of the eye with RVO at 6 months, objectively assessed by fluorescein angiography, visual acuity and visual field. The endpoint was adjudicated in 20.7% of patients treated with parnaparin (n = 28) and in 59.4% of patients treated with aspirin (n = 30) (P = 0.002). Recurrent RVO was diagnosed in 3 patients, all treated with aspirin (P = ns). Bleeding rates were similar between the two groups. Due to the small sample size of patients, the authors concluded that these promising results need to be confirmed in a larger clinical trial. 65 No clinical studies using parnaparin during 2009 were retrieved, but we are aware of an ongoing phase 3 Italian multicenter randomized clinical trial (STEFLUX trial, all active recruiting centers located in Italy) on the treatment of superf icial thrombophlebitis. The study compares the efficacy and safety of 3 different doses of parnaparin (8500 IUaXa subcutaneous, once daily for 
Tolerability and management
In all clinical trials in which parnaparin was investigated, a general good tolerability was reported. As with the other commercially available LMWHs, the most important side effect was bleeding, usually classified as major (heavy blood loss, such as clinically overt hemorrhage associated with hemoglobin drop of at least 2 g/L or requiring the transfusion of 2 or more units of packed redblood cells; or bleeding at life-threatening sites, such as retroperitonal or intracranial events; or bleeding requiring re-intervention) or minor (including, for example, bleeding at the injection site). 21, 23 Studies of thromboprophylaxis after major surgery reported of an incidence of hemorrhagic complications ranging from 1% to 4%, whereas in studies dealing with parnaparin use in unstable angina, a 3% incidence of minor bleeding and only 1 major bleeding were observed. 15, 21, 28, 32 In a study considering patients with STEMI, bleedings events occurred in 3% of patients receiving parnaparin. 23 After minor orthopedic surgery, bleeding complications were reported in 2% of the 509 patients investigated, most of which were minor bleedings (injection site hematomas). 45 In studies evaluating the use of parnaparin in peripheral vascular diseases or chronic venous disorders, minor bleeding complications and/or pain occurred less in patients allocated to subcutaneous parnaparin than in those randomized to subcutaneous UFH. 13, 32, 55, 66 Heparin-induced thrombocytopenia (HIT) is another well known complication of heparin, its incidence being approximately 0.8%, with LMWH, about 3-fold lower than with UFH. 67, 68 HIT is caused by heparindependent antibodies (usually immunoglobulin G) binding a confirmationally modified epitope on platelet factor 4 (PF4), its modified structure being subsequently recognized as a foreign protein by the immunocompetent cells of the patients. HIT was not observed in any of the clinical trials of parnaparin discussed in this review. Nonetheless, patients receiving either a prophylactic or a therapeutic course of parnaparin are recommended to carefully monitor their platelet count during the first 2 weeks of exposure to the drug, especially those with a recent history of heparin exposure, who are at higher risk of developing HIT. 5 Parnaparin is administered at different dosage according to the type and the severity of the disease. Doses and administration of parnaparin in different clinical settings are shown in Table 6 . Caution should be used in patients with renal or hepatic insufficiency, arterial hypertension, or any organ lesion subject to bleeding. 
Place in therapy and conclusion
In VTE prevention, parnaparin administered subcutaneously (3200 UIaXa) once daily for 7 days showed to be more effective than placebo (0% versus 6%, respectively) and at least as effective as UFH, in patients undergoing abdominal, vascular, orthopedic (major and minor) or cardiac surgery.
Compared to UFH, the equivalent efficacy of parnaparin given once daily for up to 3 months has been demonstrated in the treatment of CVD (above all chronic venous insufficiency secondary to a post-thrombotic syndrome), superficial trombophlebitis and DVT. 
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In patients with stable angina a 3-month course of therapy with parnaparin provides a significant improvement in the exercise time on treadmill test compared with baseline, but not in patients receiving placebo. Recently, in patients with unstable angina or STEMI, once-daily subcutaneous parnaparin has been shown to be able to significantly reduce the primary efficacy composite endpoint of death, acute MI or need for emergency myocardial revascularization (including coronary artery bypass grafting or angioplasty) in the first 7 days or 45 days after the start of treatment, respectively, compared to UFH (7% vs 11%, P = 0.034; 27% vs 42%, P = 0.03, respectively).
Subcutaneous parnaparin has been compared with placebo or UFH in patients with stage II PAOD (Leriche-Fontaine Classification). Compared with both placebo or UFH, parnaparin was able to significantly improve all the endpoints investigated, such as pain-free walking time and painfree walking distance, peak blood flow in the calf and the ankle-brachial index.
Tolerability of parnaparin has been generally reported across all studies. The risk of bleeding complications arising from parnaparin compared with UFH seems similar for the major bleeds, whereas the incidence of minor bleeds is lower with parnaparin.
No cases of HIT are reported with parnaparin use. However, a platelet count should be taken every 3 days for the first 2 weeks of treatment in all patients receiving parnaparin.
As with other LMWHs, and in contrast to UFH, parnaparin enables patients with most peripheral vascular diseases to be treated at home or as an outpatient because treatment is easy to manage, has good tolerability, equivalent efficacy and safety.
Further applications of parnaparin have been recently investigated in different settings (ulcerative colitis, RVO, severe obese patients undergoing bariatric surgery), even though its promising results on efficacy need to be confirmed in larger clinical trials.
In conclusion, parnaparin is a safe, effective, well tolerated LMWH widely investigated and used in the prevention and treatment of VTE, and in the management of CVD and of coronary artery disease. As with other LMWHs, parnaparin can be administered subcutaneously, once daily, with a better local tolerability than UFH, and the available data indicate that parnaparin could be the optimal choice among all the commercially available LMWHs.
